Daré Bioscience, Inc. Expands Leadership Team, Appointing David Friend, Ph.D. to Chief Scientific Officer
06 juin 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, June 06, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of David Friend, Ph.D., to the...
Daré Bioscience, Inc. Expands Leadership Team, Appointing Mary Jarosz, RPh, to Global Head of Regulatory Affairs
04 juin 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, June 04, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Mary Jarosz, RPh, to the...
EY Announces that Sabrina Martucci Johnson, CEO of Daré Bioscience, Inc., is an Entrepreneur Of The Year® 2018 Award Finalist in San Diego
16 mai 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, May 16, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Daré Bioscience, Inc. Announces Trial Initiation for Ovaprene® Non-Hormonal Monthly Contraceptive Candidate
15 mai 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, May 15, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Daré Bioscience, Inc. Expands Leadership Team, Appointing John Fair to Chief Business Officer
08 mai 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, May 08, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced it has appointed Mr. Fair to the newly created...
Daré Bioscience, Inc. Enters into Agreement to Acquire Product to Address Vulvar and Vaginal Atrophy in Hormone Receptor-Positive Breast Cancer Patients
07 mai 2018 08h00 HE
|
Dare Bioscience, Inc.
Agreement intends to broaden Company’s product portfolio within women’s reproductive health with novel clinical candidate, positioning Company with first in class candidates in contraception, sexual...
Daré Bioscience announces funding award to further the development of Ovaprene™ from the National Institutes of Health Eunice Kennedy Shriver National Institute of Child Health and Human Development (NICHD)
30 avr. 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, April 30, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced that it received a Notice of Award for the...
Daré Bioscience, Inc. Enters into Exclusive Worldwide License Agreement for Juniper Pharmaceuticals’ Intravaginal Ring (IVR) Technology Platform
25 avr. 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, April 25, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company focused on women’s sexual and reproductive health, announced...
Jessica Grossman, M.D., Joins Daré Bioscience Board of Directors
11 avr. 2018 08h00 HE
|
Dare Bioscience, Inc.
SAN DIEGO, April 11, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s biopharmaceutical company, today announced the appointment of Jessica Grossman, M.D., to...
Daré Bioscience, Inc. Reports 2017 Financial Results and Provides Business Update
02 avr. 2018 16h05 HE
|
Dare Bioscience, Inc.
-Conference Call and Webcast Today, April 2nd, at 4:30 PM Eastern Time- SAN DIEGO, April 02, 2018 (GLOBE NEWSWIRE) -- Daré Bioscience, Inc. (NASDAQ:DARE), a clinical-stage, women’s...